This FDA report updates the number of reported cases of patients with breast implants who develop a rare type of non-Hodgkin lymphoma. While the number of cases have increased, the number of associated deaths remains the same.
This update is relevant for anyone with breast implants including young breast cancer survivors or mutation carries who chose implants following mastectomy for treatment or prevention. This report is not generalizable to the general population of breast cancer survivors or previvors.
While this update now includes risk estimates, the FDA will continue to collect data which may impact these estimates.
Currently, removing breast implants is not recommended unless you have signs or symptoms of BIA-ALCL or are having unrelated problems with your implants.